Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
		Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016	May 31, 2016
Net sales		$ 93,964	$ 88,893	$ 286,233	$ 281,854
Cost of sales (*)	[1],[2]	35,318	34,130	109,949	106,660
Gross profit		58,646	54,763	176,284	175,194
Operating expenses:
Research and development		8,828	6,910	26,625	20,500
Selling and marketing		13,528	13,251	44,019	42,057
Distribution		4,083	4,155	12,648	12,969
General and administrative		10,046	11,779	32,111	33,133
Amortization expense		14,109	13,575	42,416	40,745
Total operating expenses		50,594	49,670	157,819	149,404
Income from operations		8,052	5,093	18,465	25,790
Non-operating income (expense):
Interest income		1	48	9	132
Interest expense		(22,981)	(22,329)	(69,203)	(67,275)
Other, net		(106)	(317)	(660)	(366)
Total non-operating expense		(23,086)	(22,598)	(69,854)	(67,509)
Loss before income taxes		(15,034)	(17,505)	(51,389)	(41,719)
Benefit for income taxes		(5,616)	(8,845)	(19,112)	(14,046)
Net loss		(9,418)	(8,660)	(32,277)	(27,673)	$ (43,767)
Net loss attributable to noncontrolling interest		(1,668)	(237)	(4,654)	(237)
Net loss attributable to shareholders of Immucor, Inc.		(7,750)	(8,423)	(27,623)	(27,436)
Net sales		93,964	88,893	286,233	281,854
Cost of sales (*)	[1],[2]	35,318	34,130	109,949	106,660
Gross profit		$ 58,646	$ 54,763	$ 176,284	$ 175,194

[1] Cost of sales is exclusive of amortization expense which is shown separately within operating expenses.

[2] Cost of sales is exclusive of amortization expense which is shown separately within operating expenses.